Search Results – Inserm Transfert

Our Technology Offers

Welcome to our Technology Offers website

You want access to an innovative offer which is based on the excellence of Inserm, the leading academic research and clinical institute dedicated to human health in Europe? Find out our technologies offers of patents and research tools: here is a sample of our patents.

MK123-T2

Drug Field of development:

Angina pectoris Therapy Area:

Product Type of patent:

Testsynchrotheracrm1904

TestsynchroPATENTCRM1904 […]

BIO16235-T1

Drug Field of development:

Metabolic Disorders Therapy Area:

Product Type of patent:

Methods of enhancing the potency of incretin-based drugs in subjects

The present invention relates to methods of enhancing the potency of incretin-based drugs in subjects in need thereof. Through different animal […]

BIO13310-T1

Drug Field of development:

Chronic Heart Failure Therapy Area:

Product Type of patent:

Apelin analogs for the treatment of heart failure

The invention related to metabolically stable Apelin analogs and their use for the prevention or the treatment of diseases mediated by the apelin […]

BIO20498-D1

Biomarker Field of development:

Gastrointestinal Diseases Therapy Area:

Method Type of patent:

Bile salts bactosensor and use thereof for diagnostic and therapeutic

Bile salts are steroid acids derived from cholesterol in the liver, are released into the gastrointestinal tract to aid in digestion and are […]

BIO18215-T1

Drug Field of development:

Hematological Disorders Therapy Area:

Product Type of patent:

Methods for increasing fetal hemoglobin content in eukaryotic cells

The clinical severity of β-hemoglobinopathies is alleviated by the co-inheritance of genetic mutations causing a sustained fetal γ-globin chain […]

BIO17684-T1

Drug Field of development:

Metabolic Disorders Therapy Area:

Product Type of patent:

Antigenic peptides deriving from pcsk2 and uses thereof for the

Despite the notion that human CD8+ T cells are the final mediators of autoimmune β-cell destruction in type 1 diabetes (T1D), none of their target […]

BIO17685-T1

Drug Field of development:

Metabolic Disorders Therapy Area:

Product Type of patent:

Antigenic peptides deriving from urocortin 3 and uses thereof for the

Despite the notion that human CD8+ T cells are the final mediators of autoimmune β- cell destruction in type 1 diabetes (T1D), none of their target […]

BIO17382-T1

Drug Field of development:

Metabolic Disorders Therapy Area:

Product Type of patent:

Antigenic peptides deriving from secretogranin v and uses thereof for

Despite the notion that human CD8+ T cells are the final mediators of autoimmune β- cell destruction in type 1 diabetes (T1D), none of their target […]

BIO19217-T1

Drug Field of development:

Hematological Disorders Therapy Area:

Product Type of patent:

Anti- protease nexin-1 conformational single domain antibodies and

The present invention relates to anti-protease nexin-1 (PN-1) conformational single domain antibodies and uses thereof in particular in the […]

BIO15170-T1

Drug Field of development:

Respiratory Disease Therapy Area:

Product Type of patent:

New antisense oligonucleotide targeting all cystic fibrosis patients

The present invention relates to methods and pharmaceutical compositions for the treatment of cystic fibrosis (CF). In particular, the present […]

147

56

310

46

Our Technology Offers

Testsynchrotheracrm1904

Methods of enhancing the potency of incretin-based drugs in subjects

Apelin analogs for the treatment of heart failure

Bile salts bactosensor and use thereof for diagnostic and therapeutic

Methods for increasing fetal hemoglobin content in eukaryotic cells

Antigenic peptides deriving from pcsk2 and uses thereof for the

Antigenic peptides deriving from urocortin 3 and uses thereof for the

Antigenic peptides deriving from secretogranin v and uses thereof for

Anti- protease nexin-1 conformational single domain antibodies and

New antisense oligonucleotide targeting all cystic fibrosis patients

You might also be interested in

Mkpatentcrmfinalmarket

Testsynchrotheracrm1904

Cd38 as a biomarker and biotarget in

Methods of enhancing the potency of incretin-based

Apelin analogs for the treatment of heart failure

Monoacylglycerol lipase as target for the

Treatment of bone mineral density related diseases

Methods and compositions for treating skin

Use of coumarin derivatives for the preparation of

Ctip fusion to cas9 enhances transgene integration

Methods and compositions for treating cell

In vitro tests allowing to identify the potential